206 related articles for article (PubMed ID: 24508555)
1. PK/TD modeling for prediction of the effects of 8C2, an anti-topotecan mAb, on topotecan-induced toxicity in mice.
Shah DK; Balthasar JP
Int J Pharm; 2014 Apr; 465(1-2):228-38. PubMed ID: 24508555
[TBL] [Abstract][Full Text] [Related]
2. Predicting the effects of 8C2, a monoclonal anti-topotecan antibody, on plasma and tissue disposition of topotecan.
Shah DK; Balthasar JP
J Pharmacokinet Pharmacodyn; 2014 Feb; 41(1):55-69. PubMed ID: 24368689
[TBL] [Abstract][Full Text] [Related]
3. Ocular and systemic toxicity of intravitreal topotecan in rabbits for potential treatment of retinoblastoma.
Buitrago E; Del Sole MJ; Torbidoni A; Fandino A; Asprea M; Croxatto JO; Chantada GL; Bramuglia GF; Schaiquevich P
Exp Eye Res; 2013 Mar; 108():103-9. PubMed ID: 23333535
[TBL] [Abstract][Full Text] [Related]
4. Mathematical modeling of topotecan pharmacokinetics and toxicodynamics in mice.
Chen J; Lu Q; Balthasar JP
J Pharmacokinet Pharmacodyn; 2007 Dec; 34(6):829-47. PubMed ID: 17885736
[TBL] [Abstract][Full Text] [Related]
5. Dynamic Contrast-Enhanced Magnetic Resonance Imaging for the Prediction of Monoclonal Antibody Tumor Disposition.
Bordeau BM; Polli JR; Schweser F; Grimm HP; Richter WF; Balthasar JP
Int J Mol Sci; 2022 Jan; 23(2):. PubMed ID: 35054865
[TBL] [Abstract][Full Text] [Related]
6. Physiologically based pharmacokinetic model for topotecan in mice.
Shah DK; Balthasar JP
J Pharmacokinet Pharmacodyn; 2011 Feb; 38(1):121-42. PubMed ID: 21104004
[TBL] [Abstract][Full Text] [Related]
7. Use of an anti-vascular endothelial growth factor antibody in a pharmacokinetic strategy to increase the efficacy of intraperitoneal chemotherapy.
Shah DK; Shin BS; Veith J; Tóth K; Bernacki RJ; Balthasar JP
J Pharmacol Exp Ther; 2009 May; 329(2):580-91. PubMed ID: 19233938
[TBL] [Abstract][Full Text] [Related]
8. Investigation of the Influence of Protein-Losing Enteropathy on Monoclonal Antibody Pharmacokinetics in Mice.
Yang Y; Li TR; Balthasar JP
AAPS J; 2017 Nov; 19(6):1791-1803. PubMed ID: 28849396
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of near infrared fluorescent labeling of monoclonal antibodies as a tool for tissue distribution.
Conner KP; Rock BM; Kwon GK; Balthasar JP; Abuqayyas L; Wienkers LC; Rock DA
Drug Metab Dispos; 2014 Nov; 42(11):1906-13. PubMed ID: 25209366
[TBL] [Abstract][Full Text] [Related]
10. Application of PBPK modeling to predict monoclonal antibody disposition in plasma and tissues in mouse models of human colorectal cancer.
Abuqayyas L; Balthasar JP
J Pharmacokinet Pharmacodyn; 2012 Dec; 39(6):683-710. PubMed ID: 23184417
[TBL] [Abstract][Full Text] [Related]
11. Population Pharmacokinetics of Oral Topotecan in Infants and Very Young Children with Brain Tumors Demonstrates a Role of ABCG2 rs4148157 on the Absorption Rate Constant.
Roberts JK; Birg AV; Lin T; Daryani VM; Panetta JC; Broniscer A; Robinson GW; Gajjar AJ; Stewart CF
Drug Metab Dispos; 2016 Jul; 44(7):1116-22. PubMed ID: 27052877
[TBL] [Abstract][Full Text] [Related]
12. Towards a platform PBPK model to characterize the plasma and tissue disposition of monoclonal antibodies in preclinical species and human.
Shah DK; Betts AM
J Pharmacokinet Pharmacodyn; 2012 Feb; 39(1):67-86. PubMed ID: 22143261
[TBL] [Abstract][Full Text] [Related]
13. Investigation of the influence of nephropathy on monoclonal antibody disposition: a pharmacokinetic study in a mouse model of diabetic nephropathy.
Engler FA; Zheng B; Balthasar JP
Pharm Res; 2014 May; 31(5):1185-93. PubMed ID: 24203494
[TBL] [Abstract][Full Text] [Related]
14. Topotecan exposure estimation in pediatric acute myeloid leukemia supported by LC-MS-based drug monitoring and pharmacokinetic analysis.
Bączek T; Konieczna L; Belka M; Maciejka-Kapuścińska L; Wiśniewski J; Niedźwiecki M; Balcerska A; Adamkiewicz-Drożyńska E; Wachowiak J
J Pharm Biomed Anal; 2012 Nov; 70():330-6. PubMed ID: 22658903
[TBL] [Abstract][Full Text] [Related]
15. Understanding the Monoclonal Antibody Disposition after Subcutaneous Administration using a Minimal Physiologically based Pharmacokinetic Model.
Varkhede N; Forrest ML
J Pharm Pharm Sci; 2018; 21(1s):130s-148s. PubMed ID: 30011390
[TBL] [Abstract][Full Text] [Related]
16. Improved Therapeutic Efficacy of Topotecan Against A549 Lung Cancer Cells with Folate-targeted Topotecan Liposomes.
Zhang J; Shi W; Xue G; Ma Q; Cui H; Zhang L
Curr Drug Metab; 2020; 21(11):902-909. PubMed ID: 32851958
[TBL] [Abstract][Full Text] [Related]
17. Liposomal topotecan formulation with a low polyethylene glycol grafting density: pharmacokinetics and antitumour activity.
Li C; Wang C; Yang H; Zhao X; Wei N; Cui J
J Pharm Pharmacol; 2012 Mar; 64(3):372-82. PubMed ID: 22309269
[TBL] [Abstract][Full Text] [Related]
18. Predicting monoclonal antibody pharmacokinetics following subcutaneous administration via whole-body physiologically-based modeling.
Hu S; D'Argenio DZ
J Pharmacokinet Pharmacodyn; 2020 Oct; 47(5):385-409. PubMed ID: 32500362
[TBL] [Abstract][Full Text] [Related]
19. A Two-Pore Physiologically Based Pharmacokinetic Model to Predict Subcutaneously Administered Different-Size Antibody/Antibody Fragments.
Li Z; Yu X; Li Y; Verma A; Chang HP; Shah DK
AAPS J; 2021 May; 23(3):62. PubMed ID: 33942169
[TBL] [Abstract][Full Text] [Related]
20. Antitumor activity of sequential treatment with topotecan and anti-epidermal growth factor receptor monoclonal antibody C225.
Ciardiello F; Bianco R; Damiano V; De Lorenzo S; Pepe S; De Placido S; Fan Z; Mendelsohn J; Bianco AR; Tortora G
Clin Cancer Res; 1999 Apr; 5(4):909-16. PubMed ID: 10213228
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
